Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Janssen-Cilag International
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Dose-Loading Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Inadequately Controlled, Moderate to Severe, Chronic Low Back Pain
The primary objectives of this study are to evaluate the analgesic effect size over 12 weeks of several doses and dosage regimens of JNJ-42160443 compared with placebo in subjects with moderate to sev...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
A study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants with Type 2 Diabetes Mellitus Estudio de los efectos de canagliflozina en los criterios de valoración renales en sujetos adultos con diabetes mellitus de tipo 2
1. To assess the effect of canagliflozin compared to placebo on progression of albuminuria. 1. Evaluar el efecto de la canagliflozina, en comparación con placebo, sobre la progresión de la album...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
Étude CR103015 : Étude de phase 1b, visant à évaluer le daratumumab (JNJ-54767414 (Humax®CD38)) en association avec les traitements de référence, chez des patients présentant un myélome multiple. [essai clos aux inclusions]
L’objectif de cette étude est d’évaluer la sécurité d’emploi, la tolérance et la dose la mieux adaptée de daratumumab à administrer en combinaison avec différents traitements de fonds, chez des patien...
Country
France
organs
Myélomes
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man
Between 18 years
and 99 years
Janssen-Cilag International N.V
Update Il y a 6 ans
Étude CR102786 : Étude de phase 3, randomisé en double aveugle, évaluant l’efficacité l’ibrutinib contre placébo, en association avec soit avec une chimiothérapie BR (bendasmustine et rituximab), soit une chimiothérapie R-CHOP (rituximab, cyclophosphamide, doxorubicine, vincristine et prednisone), chez des patients ayant un lymphome non hodgkinien indolent antérieurement traité. [essai clos aux inclusions]
L’objectif de cette étude est de comparer l’efficacité d’un traitement associant l’ibrutinib à une chimiothérapie standard de type BR (bendasmustine et rituximab) ou de type R-CHOP (rituximab, cycloph...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination with Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
The primary objective of this study is to evaluate whether the addition of ibrutinib to bendamustine and rituximab will result in prolongation of PFS in subjects with newly diagnosed MCL who are 65 ye...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
An open label study to evaluate the efficacy, safety and tolerability of RWJ333369 as adjunctive therapy in subjects with partial onset seizure
The primary objective of this open label study is to determine the long-term safety and tolerability of RWJ-333369 as adjunctive treatment of partial onset seizures. Safety evaluation will include wor...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
To evaluate the efficacy of guselkumab compared with secukinumab for the treatment of subjects with moderate to severe plaque-type psoriasis.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
Update Il y a 4 ans
A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study in Type 2 Diabetes Mellitus Subjects to Evaluate the Efficacy, Safety and Tolerability of MTP Inhibitor JNJ-16269110
The primary objective of this study is to evaluate the effect of 12-week treatment with JNJ-16269110 on the glycated hemoglobin (HbA1c) concentration in subjects with T2DM.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
SELENE : Essai de phase 3 randomisé, en double aveugle, évaluant l’efficacité et la tolérance de l’ibrutinib associé à une chimiothérapie associant le rituximab, le cyclophosphamide, la doxorubicine, la vincristine et la prednisone (R-CHOP) ou une chimiothérapie associant la bendamustine et le rituximab (BR), chez des patients ayant un lymphome non hodgkinien indolent à cellules B. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité et la tolérance de l’ibrutinib en association avec une chimiothérapie, chez des patients ayant un lymphome non hodgkinien indolent à cellules B. Les...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
Study to evaluate optimized retreatment and prolonged therapy with bortezomib
The objective of this study is to describe the effect of optimized retreatment with bortezomib in combination with dexamethasone followed by prolonged therapy with bortezomib, versus standard retreatm...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next